Liu Lei, Xu Qian, Cheng Luyang, Ma Chunhu, Xiao Lijun, Xu Dawei, Gao Yaxian, Wang Jianping, Song Hongru
Department of Immunology, Basic Medical Institute, Chengde Medical College, Chengde, Hebei 067000, P.R. China.
Department of Central Laboratory, Basic Medical Institute, Chengde Medical College, Chengde, Hebei 067000, P.R. China.
Oncol Lett. 2015 Feb;9(2):891-896. doi: 10.3892/ol.2014.2721. Epub 2014 Nov 20.
The aim of the current study was to evaluate a novel tumor marker, neuropeptide Y receptor Y1 (NPY1R), for the detection of circulating cancer cells and to investigate its clinical significance in breast cancer patients. The Digital Gene Expression Displayer tool of the Cancer Genome Anatomy Project was used to identify the marker gene NPY1R, which is able to detect circulating cancer cells. Nested quantitative polymerase chain reaction was performed to correlate the NPY1R expression levels with the clinicopathological features of 142 breast cancer patients. A follow-up study of 131 of the breast cancer patients was conducted for 38 months. Compared with the 60 normal control individuals, NPY1R was highly expressed in the cancer patients (P<0.01). These high levels of NPY1R expression were positively correlated with the clinical stage and lymph node metastasis status of the disease, as well as with the status of the estrogen and progesterone receptors (P<0.05). Breast cancer patients with circulating cancer cells that expressed NPY1R exhibited shorter tumor-specific survival when compared with those with no NPY1R expression (P<0.01). Additionally, the mortality rate was associated with HER2 expression in the NPY1R positive and negative groups. These results indicate that NPY1R may serve as a useful marker to predict breast cancer metastasis and to evaluate the prognosis of breast cancer patients.
本研究的目的是评估一种新型肿瘤标志物——神经肽Y受体Y1（NPY1R），用于检测循环肿瘤细胞，并研究其在乳腺癌患者中的临床意义。利用癌症基因组解剖计划的数字基因表达显示工具来鉴定能够检测循环肿瘤细胞的标志物基因NPY1R。采用巢式定量聚合酶链反应将142例乳腺癌患者的NPY1R表达水平与临床病理特征进行关联。对131例乳腺癌患者进行了为期38个月的随访研究。与60名正常对照个体相比，NPY1R在癌症患者中高表达（P<0.01）。这些高水平的NPY1R表达与疾病的临床分期、淋巴结转移状态以及雌激素和孕激素受体状态呈正相关（P<0.05）。与无NPY1R表达的乳腺癌患者相比，表达NPY1R的循环肿瘤细胞的乳腺癌患者的肿瘤特异性生存期较短（P<0.01）。此外，NPY1R阳性和阴性组的死亡率与HER2表达有关。这些结果表明，NPY1R可能作为预测乳腺癌转移和评估乳腺癌患者预后的有用标志物。
